<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03152955</url>
  </required_header>
  <id_info>
    <org_study_id>XiangyaHospital</org_study_id>
    <nct_id>NCT03152955</nct_id>
  </id_info>
  <brief_title>Postoperative Analgesia in Patients With Microvascular Decompression</brief_title>
  <official_title>Efficacy and Safety of Multimodal Analgesia Used in Patients With Microvascular Decompression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangya Hospital of Central South University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perioperative pain is caused by a variety of harmful factors through multiple mechanisms,
      therefore, reasonable postoperative analgesia should be combined with drugs or measures of
      different mechanism , which is called multimodal analgesia. Multimodal analgesia could
      minimize side effects and achieve a better analgesic effect. Commonly used strategies of
      multimodal analgesia are oral analgesic drug, nerve block, patient controlled analgesia and
      so on. This study will observe the effect of multimodal analgesia on postoperative pain in
      patients with microvascular decompression and record side effects. Finally, it will provide
      technical support for the guidance of postoperative analgesia in patients of trigeminal
      neuralgia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will collect 90 cases which will be divided into 3 groups. Patients in
      Group A will receive scalp nerve block and patient-controlled analgesia which contains
      sufentanil and ondansetron. In Group B, patient-controlled analgesia which contains
      sufentanil, ondansetron and ketamine will be applied. In Group C, patient-controlled
      analgesia which contains sufentanil and ondansetron will be applied.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Anticipated">May 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual analog scale score</measure>
    <time_frame>6 hour after operation</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Trigeminal Neuralgia</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Group A will receive scalp nerve block and patient-controlled analgesia which contains sufentanil and ondansetron.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Group B, patient-controlled analgesia which contains sufentanil、ondansetron and ketamine will be applied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>In Group C, patient-controlled analgesia which contains sufentanil and ondansetron will be applied.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine will be applied in patient-controlled analgesia.</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>scalp nerve block</intervention_name>
    <description>Scalp nerve block is performed for the blockade of the greater occipital, superficial cervical and lesser occipital nerves with 0.5% ropivacaine.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron</intervention_name>
    <description>Ondansetron(13ug/kg/h) is applied in patient-controlled analgesia.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>Sufentanil(0.02ug/kg/h) is applied in patient-controlled analgesia.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients of trigeminal neuralgia plan to receive microvascular decompression

          2. Age between 18 and 70, ASA classification between Ⅰ～Ⅲ

          3. No severe liver and kidney disease, no blood coagulation dysfunction

          4. No history of long-term opioid drugs usage, no drug addiction history

          5. Patients are fully conscious, cooperation, understanding and voluntarily signed
             informed consent

        Exclusion Criteria:

          1. More than 20% of the total blood volume is lost in operation

          2. Intracranial hematoma happens within 24 h after surgery

          3. Secondary surgery patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xie Yongqiu</last_name>
    <role>Study Director</role>
    <affiliation>Xiangya Hospital of Central South University in Changsha</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>trigeminal neuralgia</keyword>
  <keyword>nerve block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Trigeminal Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

